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Effect of sacubitril/valsartan on inflammation and oxidative 
stress in doxorubicin-induced heart failure model in rabbits
Our study evaluates the effects of sacubitril/valsartan 
(SAC/VAL) in the rabbit model of doxorubicin-induced 
heart failure. Twenty rabbits (5 per group) were adminis-
tered with doxorubicin (DOX, 1.5 mg kg–1, i.v.) to induce 
heart failure. Specific biomarkers such as BNP, CnT, CRP 
and ROMs were determined. The cardiac enzymatic anti-
oxidant systems were recorded with their electrographic 
profiles. HR, SBP, DBP and MAP were restored at 5 or 10 mg 
kg–1 (p.o.) of SAC/VAL compared to DOX, followed by re-
duced levels of creatinine and BNP (p < 0.001). Significant 
improvements (p < 0.05) compared to DOX were also noti-
ced in CAT, SOD and LPO with the same doses of SAC/
VAL. Specific biomarkers such as BNP, CnT, CRP and ROMs 
descended significantly (p < 0.001) with treatment when 
compared to their baseline values. Our findings implied 
that SAC/VAL treatment reduced the inflammation and 
oxidative stress to improve the cardiac function. 
Keywords: sacubitril, valsartan, doxorubicin-heart failure, 
inflammation, oxidative stress, natriuretic peptide
Heart diseases are present all over the world (1). The characteristics of heart failure 
include reduced myocardial function with reduced stroke volume and cardiac output (2). 
The reduction in myocardial activity may be attributed to many causes, such as cardio-
myopathy, ageing and free radical degradation (3–5). Of the several reasons for the redu-
ced stroke volume and cardiac output, coronary artery endothelium inflammation and 
increased oxidative stress contribute mainly to heart failure (6, 7). Doxorubicin causes 
heart failure with ventricular wall thinning accompanied by left ventricular damage 
 resulting in increased dilation. Doxorubicin-induced cardiomyopathy involves various 
underlying mechanisms that result in mitochondrial injury, myocardial cell intracellular 
dysfunction and increased calcium ion flux with reduced ejection output. Changes in myo-
cardial vulnerability may include elevation of biochemical biomarkers and endothelial 
injury with increased levels of enzymes such as catalase, oxidase, etc., resulting in inflam-
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The treatment of heart failure includes cardiotonics, angiotensin-converting enzyme 
inhibitors, beta-blockers, selective angiotensin-II receptor inhibitors, followed by many 
others (8). Although treatment for heart failure involves the use of several standard thera-
peutic drugs, inflammation and oxidative stress interventions are often ignored, resulting 
in a significant increase in morbidity, mortality and health care costs (9). Sacubitril (SAC) 
is a natriuretic peptide inhibitor and valsartan (VAL) is the angiotensin-II peptide inhibitor 
(10) used in the treatment of heart failure, hypertension, myocardial infarction with left 
ventricular dysfunction and coronary heart disease (11). They act primarily by inhibiting 
the natriuretic peptide system and by binding to the angiotensin-II receptors, resp. (12). 
Several studies (12, 13) documented their therapeutic use in inflammation and oxidative 
stress by inhibiting nitric oxide release and the cascade of inflammatory mediators such 
as cytokines.
The latest US FDA’s Entresto (SAC/VAL) approval was a significant step in the man-
agement of heart failure with reduced ejection fraction (HFrEF) due to improved clinical 
outcomes (14). Eventually, a study by Trivedi et al. (13) published evaluating the SAC/VAL 
effects in a rat model of HFrEF, demonstrated an endothelial function improvement with 
an increase in bioavailability of nitric oxide and a decrease in arterial strength and stiff-
ness. Additionally, in an ischemic model of HFrEF in streptozotocin-induced diabetic mice, 
the antifibrotic ability of SAC/VAL was greater than that of VAL alone, possibly by reduc-
ing the transforming growth factor-β (15). Until today, no study has reported the effective-
ness of sacubitril/valsartan in doxorubicin-induced cardiac failure in rabbits. Therefore, 
our research aims to investigate the effects of SAC/VAL in doxorubicin-induced heart fail-
ure in rabbits and to validate their role in inflammation and oxidative stress.
EXPERIMENTAL
Chemicals and drugs
The drugs and chemical constituents required, such as sacubitril/valsartan (SAC/
VAL, Entresto 49/51 tablets, equivalent to 48.6 mg sacubitril and 51.4 mg valsartan, a so-
dium salt complex) (Novartis, Switzerland) and doxorubicin hydrochloride (≥ 95 % purity, 
DOX) were obtained from Novartis Pharma AG (Switzerland) as gift samples. The sub-
stances such as ketamine hydrochloride, heparin, phenylephrine, sodium nitroprusside, 
acetylcholine, inorganic salts, dextrose and ethylenediaminetetraacetic acid were pro-
cured from Sigma-Aldrich (USA).
Animals
Twenty male adult New Zealand white rabbits (age 12 weeks, weighing about 2–3 kg) 
were obtained from the Institute of Laboratory Animal Sciences, Jilin (China) for this 
study. They were housed in metal cages (humidity 20 %) at room temperature (25 °C) in a 
12-h dark and 12-h light cycle, providing a free supply of food, water, and other necessities. 
The study protocols were previously approved by the Institutional Ethics of Animal Com-
mittee, and all experimental studies were carried out in accordance with the Animal 
 Ethical Guidelines rules and regulations.
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Experimental design
The induction of heart failure was done following the methods described by Romão 
et al. (12) with minor alterations. Doxorubicin (1.5 mg kg–1, i.v.) was given once a week for 
five weeks. For each week of doxorubicin administration, the rabbits were classified into 
four groups with five animals in each group – 1 – one naïve or control group (containing 
the animals who received distilled water only), 2 – DOX group (where rabbits received 
doxorubicin only), 3 – SAC/VAL 5 mg kg–1 and 4 – SAC/VAL 10 mg kg–1. The combined dose 
of SAC/VAL was given orally once a day for four weeks, beginning from the second week 
of doxorubicin administration. SAC/VAL doses were based on the drug composition with 
a 1:1 mass ratio of sacubitril to valsartan described in the PARADIGM-HF trial and the 
highest dose of VAL reported in rabbits was 10 mg kg–1 day–1 (16, 17). Hence, we selected 5 
or 10 mg kg–1 SAC/VAL doses (approximately, 2.45 mg SAC+ 2.55 mg VAL in case of 5 mg, 
and 4.9 mg SAC+ 5.1 mg VAL in case of 10 mg). Each of SAC/VAL (Entresto) was suspended 
in 0.5 % carboxymethyl cellulose and administered via oral gavage in a volume of 2 mL kg–1 
body mass.
In a separate pilot study, the optimal dose of SAC/VAL (2.5, 5 or 10 mg kg–1) was deter-
mined in adult health male New Zealand Wister rabbits (3 per group). Measured pharma-
codynamics effects involved hemodynamic parameters and atrial natriuretic peptide 
(ANP) test to assess the inhibition of neprilysin following treatment with SAC/VAL (5 or 
10 mg kg–1), followed by cGMP analysis after injecting atrial natriuretic peptide (40 mg kg–1 
i.v.). We selected 5 and 10 mg kg–1 doses of SAC/VAL based on the hemodynamic responses 
and significant escalation in cGMP plasma levels after the ANP test.
No animal deaths were recorded in any of the groups during daily recording. At the 
end of the study period (36th day), the animals were given diazepam (10 mg kg–1) and ket-
amine (115 mg kg–1) to induce anesthesia and to alleviate discomfort to carry out cannula-
tion and collection of blood samples from the left carotid artery.
Electrocardiography and assessment of blood pressure
The rabbits were anesthetized as described above prior to the positioning of elec-
trodes on elbows and knees (RL, LL, LA and RA). The electrocardiogram was recorded 
using an ECG machine (BPL Cardiart 108T ECG Machine, China), with electrodes V1, V2, 
V3, V4, and V5.
The animals were given heparin (45 IU kg–1) subcutaneously. The left carotid artery 
was exposed and cannulated, then attached to the blood pressure recording system 
 (PowerLab®) through the pressure transducer (Blood pressure transducer, China). The 
changes in heart rate (HR, beats min–1), mean arterial pressure (MAP), systolic (SBP) and 
diastolic blood pressure (DBP) were recorded for 15 minutes.
Biochemical parameters
Blood samples obtained from the left carotid artery were centrifuged at 2000×g for 15 
min to separate serum. The parameters such as alanine aminotransferase (ALT), albumin, 
aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT), total cholesterol (TC), 
high-density lipoprotein cholesterol (HDL-C), indirect, direct and total bilirubin, alkaline 
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phosphatase (ALP), creatinine, triglycerides, urea, uric acid and the levels of Na+ and K+ 
were determined using a biochemical analyzer (Bioline Technologies, China). Enzyme-
linked immunosorbent assay (ELISA) (Bioline Technologies, India) determined the levels 
of brain natriuretic peptide (BNP) and troponin.
Cardiac enzymes responsible for antioxidant activity
After the completion of blood sample collection, electrocardiogram and blood pres-
sure measurements, the heart tissues were immediately collected after euthanasia by in-
travenous administration of 20 % (m/V) potassium chloride and were homogenized in 
phosphate buffer (pH 6.8). Activities of enzymes such as catalase (CAT), superoxide dis-
mutase (SOD), and lipid hydroxyperoxidase (LPO) were determined according to Romão 
et al. (12) and expressed as mmol min–1 g–1 tissue for CAT activity, IU g–1 of tissue for SOD 
activity and mmol hydroperoxide g–1 of tissue for LPO levels.
Analysis of specific biomarkers
Centrifugation of blood samples was done instantly at 1500×g for 15 min at room tem-
perature, and the separated serum was stored at –4 °C until analyzed. The serum C-reac-
tive protein was determined by nephelometer (Behring Nephelometer BN II analyser, Sie-
mens Healthineers, Germany) using monoclonal anti-CRP antibodies. Consequently, 
reactive oxygen metabolites (ROM) were measured based on Fenton radical reaction by 
photometer at 535 nm. This measurement involves the estimation of serum hydroper-
oxides formed from free radicals, thus quantifying the amount of ROMs produced.
Statistical analysis
The results were represented as mean ± SEM. The variations among groups were esti-
mated using analysis of variance (ANOVA), followed by Dunnett’s t-test. The skewed 
variations among the values of serum cardiac troponin (CnT), BNP (brain-type natriuretic 
peptide), CRP (C-reactive protein), and reactive oxygen metabolites (ROM) were trans-
formed into logarithms for analysis. The variations between groups, determined using 
 t-tests (paired) were used for continuous variables to compare intra- and inter-group 
 variations.
RESULTS AND DISCUSSION
Effects of SAC/VAL on blood pressure
Heart rate, systolic blood pressure, diastolic blood pressure and mean arterial pres-
sure were recorded for 15 min. The heart rate was found to increase significantly in the 
group receiving 5 or 10 mg kg–1 SAC/VAL (p < 0.01); however, SBP and DBP decreased in 
both the treatment groups (p = 0.002) when compared to the DOX group. MAP was 71.67 ± 
4.60 mm Hg in the DOX group and descended to 44.1 ± 2.48 and 46.77 ± 2.52 mm Hg after 
treatment with 5 and 10 mg kg–1 SAC/VAL, resp. (Fig. 1). No significant differences were 
found when treatment groups were compared with the naive group.
477
C. Yu et al.: Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits, 
Acta Pharm. 71 (2021) 473–484.
 
Effects on the electrocardiography
The prolongation of the PR segment was significantly greater in the DOX group (p = 
0.0166) relative to naïve rabbits but no difference was observed in 5 or 10 mg kg–1 SAC/VAL 
groups Such significant changes were due to the effect of doxorubicin altering cardiac 
potassium channels. The down-regulation of these channels by doxorubicin activates the 
caspase activity which changes the heart’s electrical activity (18). There was a substantial 
decrease in QTC segment prolongation and QT interval prolongation (p < 0.001) in SAC/
VAL (5 and 10 mg kg–1) groups as compared to the DOX group. Q-wave amplitude was 
similar to the naïve group in 5 and 10 mg kg–1 SAC/VAL groups but it significantly in-
creased (p < 0.001) in the DOX group (Fig. 2). Changes in repolarization in the myocardium 
are due to altered QT-segment and Q-wave (19).
Effects of SA/VAL on biochemical parameters
The AST levels increased in 5 and 10 mg kg–1 SAC/VAL groups when compared with 
the DOX group. The ALT levels remained identical in all groups (Table I) with no signifi-
cant changes compared to the naïve group. The creatinine levels of the DOX group were 
observed to be significantly (p < 0.001) higher than in the naïve and treatment groups. 
Increased serum creatinine levels in the DOX group indicate shifts in renal clearance 
Fig. 1. Graphical representation of the changes in the heart rate, blood pressure in naïve, DOX and 
SAC/VAL (5 mg kg–1 or 10 mg kg–1) groups. Values are expressed as mean ± SEM (n = 5). Significant 
difference: versus naïve group *p < 0.05; versus DOX group: **p < 0.05 and ***p < 0.001 (using one-way 
ANOVA, including Dunnett’s test).
a)                                                                 b)
c)                                                                 d)
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which are partly caused by the deterioration of kidney cells or a gradual reduction in 
cardiac output that is caused by cardiac failure. Additionally, we found a significant in-
crease (p < 0.001) in BNP levels in the DOX group as compared to naïve and treatment 
groups (Table I).
Table I. Serum analysis of biomarkers and biochemical parameters of naïv, DOX or SAL/VAL rabbits
Parameter Naïve DOX (1.5 mg kg–1, i.v.)
SAL/VAL 
(5 mg kg–1, per os)
SAL/VAL 
(10 mg kg–1, per os)
Albumin 
(g per 100 mL) 2.84 ± 0.20 2.95 ± 0.15 2.77 ± 0.22 2.99 ± 0.09
AST (U L–1) 32.5 ± 1.7 25.9 ± 1.5* 31.37 ± 1.01 30.13 ± 1.04
ALT (U L–1) 19.47 ± 1.05 20.33 ± 1.47 19.80 ± 0.81 18.83 ± 1.16
Total bilirubin 
(mg per 100 mL) 0.066 ± 0.009 0.063 ± 0.009 0.066 ± 0.012 0.067 ± 0.012
Creatinine 
(mg per 100 mL) 1.00 ± 0.10 2.67 ± 0.26* 0.87 ± 0.06 0.89 ± 0.06
Urea 
(mg per 100 mL) 26.43 ± 1.20 28.70 ± 2.02 27.53 ± 1.86 27.30 ± 0.53
Uric acid 
(mg per 100 mL) 0.247 ± 0.009 0.233 ± 0.019 0.233 ± 0.014 0.227 ± 0.019
Triglycerides 
(mg per 100 mL) 92.27 ± 1.70 87.87 ± 0.97 90.20 ± 0.61 91.53 ± 0.50
Total cholesterol 
(mg per 100 mL) 42.53 ± 0.65 45.43 ± 1.24 43.13 ± 1.30 43.03 ± 1.30
HDL-C 
(mg per 100 mL) 24.03 ± 1.49 22.50 ± 0.44 24.40 ± 0.91 23.33 ± 1.75
GGT (U L–1) 4.89 ± 0.13 5.04 ± 0.07 4.86 ± 0.08 4.44 ± 0.50
ALP (U L–1) 24.03 ± 1.69 26.07 ± 0.54 24.8 ± 0.89 26.3 ± 1.56
Na+ (mmol L–1) 111.2 ± 4.7 103.2 ± 3.7 108.5 ± 1.6 103.1 ± 3.4
K+ (mmol L–1) 4.64 ± 0.27 4.57 ± 0.25 5.01 ± 0.03 4.36 ± 0.34
Cardiac troponin 
(ng mL–1) 0.02 ± 0.005 0.025 ± 0.007 0.02 ± 0.005 0.04 ± 0.005
BNP (ng L–1) 89.37 ± 1.9 406.5 ± 4.23* 87.6 ± 1.47** 83.97 ± 1.96**
ALT – alanine aminotransferase, AST – aspartate aminotransferase, ALP – alkaline phosphatase, BNP – serum 
N-terminal pro-brain type natriuretic peptide, GGT – gamma-glutamyl transpeptidase, HDL-C – high-density 
 lipoprotein cholesterol
Data are represented as mean ± SEM (n = 5).
Statistically significant: *p < 0.05 against naïve; **p < 0.001 against DOX group (using one-way ANOVA, including 
Dunnett’s test).
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Effect on the cardiac antioxidant defense system
SOD levels in 5 and 10 mg kg–1 SAC/VAL groups increased significantly compared 
with the DOX group. The CAT level in the DOX group increased significantly (p = 0.0027) 
after treatment with 5 or 10 mg kg–1 SAC/VAL, thus restoring the normal value of the naïve 
group. These results indicate that DOX resulted in the development of free radicals in the 
heart tissue which reduced ROS detoxification. The levels of LPO increased significantly 
(p < 0.05) in 5 and 10 mg kg–1 SAC/VAL groups when compared to the naïve group and 
decreased significantly (p < 0.001) when compared to the DOX group. Increased levels of 
Table II. Oxidative enzymes of naïve, DOX or SAL/VAL rabbits
Parameter Naïve DOX (1.5 mg kg–1, i.v.)
SAC/VAL 
(5 mg kg–1, per os)
SAC/VAL 
(10 mg kg–1, per os)
SOD 
(IU g–1 tissue) 40.50 ± 0.57 17.77 ± 0.81* 35.3 ± 1.5*** 38.13 ± 2.77***
Catalase 
(mmol min–1 g–1 tissue) 4.50 ± 0.34 2.567 ± 0.176* 2.467 ± 0.200** 3.467 ± 0.210**
Lipid peroxidation 
(nmol H2O2 g–1 tissue)
334.3 ± 4.6 1857.4 ± 32.6* 703.5 ± 35.8*** 799.5 ± 20.1***
SOD – superoxide dismutase.
Data are represented as mean ± SEM (n = 5).
Statistically significant: *p < 0.05 against naïve; **p < 0.01, ***p < 0.001 against DOX group (using one-way ANOVA, 
including Dunnett’s test).
Table III. Changes in specific biomarker levels between SAC/VAL groups
Parameter
SAC/VAL 
(5 mg kg–1, per os)
SAC/VAL 
(10 mg kg–1, per os)
Before After Before After
Serum N-terminal pro-brain type 
natriuretic peptide (BNP) (log pg mL–1) 3.73 ± 0.12 2.33 ± 0.14** 3.70 ± 0.11 2.03 ± 0.07*
,**
Serum high-sensitivity cardiac troponin 
(CnT) (log ng mL–1) 1.83 ± 0.03 1.53 ± 0.03** 1.8 ± 0.06 1.1 ± 0.05*
,**
Serum high-sensitivity C-reactive protein 
(CRP) (log ng mL–1) 3.7 ± 0.06 2.8 ± 0.05** 3.667 ± 0.089 2.103 ± 0.054*
,**
Reactive oxygen metabolites (ROMs) 
(U.CARR.)a 410 ± 6 340 ± 10** 300 ±131 326 ± 18*
,**
Data are expressed as mean ± SEM (n = 5).
Statistical significance: *p < 0.05 between both SAC/VAL groups after treatment; **p < 0.001 between before and 
after treatments of SAC/VAL (5 mg kg–1 or 10 mg kg–1) employing paired t-test.
a One U.CARR. corresponds to 0.8 mg L–1 hydrogen peroxide.
481
C. Yu et al.: Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits, 
Acta Pharm. 71 (2021) 473–484.
 
LPO confirm the presence of oxidative stress. Cardiac myopathy may be a resultant factor 
of ROS produced by doxorubicin (20, 21). Therefore, SAC/VAL treatment was able to restore 
the enzymatic levels in heart failure (22) (Table II).
Effects on the specific biomarkers
The levels of serum natriuretic peptide, cardiac troponin and C-reactive protein 
showed a significant (p < 0.001) decrease in 5 and 10 mg kg–1 SAC/VAL treated groups when 
compared to DOX values before the treatment (Figs. 3, 4). Likewise, there was a significant 
decrease of reactive oxygen metabolites (ROMs) in both SAC/VAL groups when compared 
to the DOX group (Figs. 3, 4 and Table III). Inflammatory biomarkers such as CRP, CnT, 
BNP, and oxidative stress markers such as ROM increased after treatment with SAC/VAL 
(both doses) indicating their anti-inflammatory and antioxidant effects in agreement with 
the study of Angelis et al. (23) where cardiac failure was a result of reduced activity of 
antioxidant enzymes and specific biomarkers (hsCRP, BNP, and CT) (24, 25).
Our findings showed that the highest dose of SAC/VAL (10 mg kg–1) showed a signifi-
cant antioxidant effect, with reduced lipid proliferation, thus acting as a free radical scav-
enger in accordance with the study reporting that oxidative stress was involved in causing 
cardiotoxicity in patients (12, 13, 23, 26). Our results are consistent with previous studies 
(27) concerning the antioxidant activity of SAC/VAL with reduced hsTnT and NT-ProBNP. 
Another research (12) found an increase in myocardial permeability promoting the release 
of troponin, suggesting that inflammation triggers the release of cardiac troponin in DOX-
induced heart failure and thus supports our study findings. Additionally, Jing et al. (27) 
suggested that SAC/VAL suppressed the expression of proinflammatory cytokines in rat/
rabbit cardiac failure models indicating inflammatory actions of SAC/VAL. This was fur-
ther supported by our findings in which CRP and cardiac troponin levels were reduced 
significantly (p < 0.001) after treatment with 5 and 10 mg kg–1 SAC/VAL in DOX-induced 
heart failure.
Limitations of the study
Histological (cellular) and molecular-level analysis may be needed to determine the 
role of SAC/VAL treatment in heart failure caused by doxorubicin. The biochemical criteria 
used in the current study have shortcomings in correlating the cardiac performance and 
measures of renal or hepatic dysfunction in doxorubicin-induced heart failure.
CONCLUSIONS
Our findings suggest the restorative effect of SAC/VAL in doxorubicin-induced heart 
failure, which is due to a decrease in the systolic and diastolic blood pressure and mean 
arterial pressure, followed by an increase in heart rate. Our study also found that SAC/VAL 
prevented heart failure induced by doxorubicin, by reducing serum BNP, cardiac troponin, 
and CRP levels, indicating suppressed inflammatory action. Due to SAC/VAL treatment, 
ROMs and various enzymatic activities were reduced as well, which improved the cardiac 
function offering cardiac protection in heart failure. However, the exact mechanism of 
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SAC/VAL in reducing the inflammation and oxidative stress is yet to be understood, in-
creasing the need for further studies.
Abbreviations, acronyms, symbols. – ALT – alanine aminotransferase, ANP – atrial natriuretic pep-
tide, AST – aspartate aminotransferase, BNP – brain natriuretic peptide, CAT – catalase, cGMP – cy-
clic guanosine monophosphate, CnT – cardiac troponin, CRP – C-reactive protein, DBP – diastolic 
blood pressure, DOX – doxorubicin, ECG – electrocardiogram, ELISA – enzyme-linked immunosor-
bent assay, GGT – gamma-glutamyl transferase, HFrEF – heart failure with reduced ejection fraction, 
HDL-c – high-density lipoprotein cholesterol, HR – heart rate, hsCRP – high sensitivity C-reactive 
protein, hsTnT – high sensitivity troponin T, LPO – lipid hydroxyl peroxidase, MAP – mean arterial 
pressure, NPS – natriuretic peptide system, NT-ProBNP – N-terminal pro-brain natriuretic peptide, 
ROM – reactive oxygen metabolites, SAC – sacubitril, SBP – systolic blood pressure, SOD – superoxide 
dismutase, TC – total cholesterol, VAL – valsartan.
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